Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QQSBZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LCB-97
|
|||||
| Synonyms |
LCB 97; LCB-97
Click to Show/Hide
|
|||||
| Organization |
LegoChem Biosciences, Inc.; Elthera AG
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 6 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
Colorectal cancer [ICD11:2B91]
Clinical candidate
Melanoma [ICD11:2C30]
Clinical candidate
Ovarian cancer [ICD11:2C73]
Clinical candidate
Pancreatic cancer [ICD11:2C10]
Clinical candidate
Small cell lung cancer [ICD11:2C25]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
AF4/FMR2 family member 4 (AFF4)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
LCBs ConjuAllTM platform technology.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.